Premium
Liposomal amphotericin B (AmBisome ® ) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis
Author(s) -
Cordonnier C.,
Bresnik M.,
Ebrahimi R.
Publication year - 2007
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2007.01362.x
Subject(s) - aspergillosis , voriconazole , amphotericin b , mycosis , amphotericin b deoxycholate , antifungal , medicine , microbiology and biotechnology , aspergillus , biology , immunology , caspofungin
Summary A pooled efficacy analysis applying current diagnostic standards for case selection was performed on previously published trials of liposomal amphotericin B for invasive filamentous fungal infections (IFFI). Favourable responses were observed in 51% of microbiologically confirmed cases of proven or probable IFFI. Despite the limitations inherent in a retrospective analysis of pooled studies, the response rates observed in this analysis were consistent with previous reports for antifungal therapy with amphotericin B deoxycholate or voriconazole in the treatment of invasive aspergillosis.